Navigation Links
Study finds genomic differences in types of cervical cancer
Date:8/23/2013

BOSTON A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

The study, published August 23, 2013 in the online version of the journal Cancer by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital (BWH), is the first to compare the spectrum of cancer-related gene mutations in the two main subtypes of cervical cancer adenocarcinoma and squamous cell carcinoma. In tests on 80 cervical tumor samples, the investigators found high rates of mutations in two genes: PIK3CA and KRAS. While PIK3CA mutations appeared in both subtypes, KRAS mutations were found only in adenocarcinomas.

By linking their findings to data on patients' treatment and survival, researchers found that PIK3CA mutations are associated with a shorter survival period: patients whose tumors carried these mutations lived a median of 67 months after diagnosis compared with 90 months for patients whose tumors lacked the mutations.

"We have historically treated cervical cancers as one disease," says the study's lead author, Alexi Wright, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber. "However, our findings suggest that some patients may be at higher risk of dying from their disease and might benefit from a more tailored treatment approach."

The discovery of high rates of PIK3CA mutations in the cervical tumor samples suggests that many patients could benefit from drugs known as PI3-kinase inhibitors, which target the family of proteins associated with the gene, the authors say. Patients with the adenocarcinoma subtype of cervical cancer may benefit from targeted agents known as MEK inhibitors, which have shown some success in clinical trials.

Cervical cancer is the second leading cause of cancer deaths among women worldwide, responsible for 275,000 deaths annually. While Pap tests have helped decrease the incidence of squamous cell cervical cancer, adenocarcinomas now account for nearly a quarter of all cervical cancers, up from 5 percent 20 years ago.

In the study, investigators probed the DNA of 80 cervical cancer tumors 40 adenocarcinomas and 40 squamous cell carcinomas for 1,200 mutations in hundreds of genes linked to cancer. The probe was done with OncoMap, a system developed at Dana-Farber to test large numbers of tumor samples for cancer-related genes. They found that 31 percent of the samples had PIK3CA mutations; 17.5 percent of the adenocarcinomas (and none of the squamous cell carcinomas) had KRAS mutations; and 7.5 percent of the squamous cell carcinomas (but none of the adenocarcinomas) had a rare mutation in the gene EGFR.

"While current treatment strategies don't take into account whether cervical tumors are adenocarcinomas or squamous cell carcinomas, our study suggests that identifying and targeting distinct subsets of patients may improve outcomes for women with early or late-stage disease," Wright comments.


'/>"/>

Contact: Robbin Ray
robbin_ray@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. LSUHSC study reports racial/ethnic differences in young people with cancer
2. 246 Study Participants Reported the Health Benefits of the TA-65 Telomerase Activator
3. Single injection may revolutionize melanoma treatment, Moffitt study shows
4. Study helps explain increased melanoma risk in individuals with red hair
5. UCLA Nursing study suggests focus on lifestyle changes -- not weight loss -- is key to kids health
6. Study finds grandmothers who raise their grandkids struggle with depression
7. Study: Disease caused by repeat brain trauma in athletes may affect memory, mood, behavior
8. Case study collection diagnostic dilemmas hones physicians skills
9. Shocking New CDC Study Confirms U.S. Tick-Borne Disease Epidemic, Shows Lyme Disease Rates 10X Higher than Previously Reported
10. Penn Medicine study shows survivorship care plans empower cancer patients
11. UCLA study suggests iron is at core of Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... for mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... solutions to the network of the Tennessee Counseling Association, adding exclusive benefits and ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: